| Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases S Maramai, S Gemma, S Brogi, G Campiani, S Butini, H Stark, M Brindisi Frontiers in neuroscience 10, 451, 2016 | 96 | 2016 |
| Multitarget therapeutic strategies for Alzheimer’s disease: Review on emerging target combinations S Maramai, M Benchekroun, MT Gabr, S Yahiaoui BioMed Research International 2020 (1), 5120230, 2020 | 78 | 2020 |
| Development and pharmacological characterization of selective blockers of 2-arachidonoyl glycerol degradation with efficacy in rodent models of multiple sclerosis and pain M Brindisi, S Maramai, S Gemma, S Brogi, A Grillo, L Di Cesare Mannelli, ... Journal of medicinal chemistry 59 (6), 2612-2632, 2016 | 78 | 2016 |
| Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABAAR) Modulators Acting at the Benzodiazepine Binding Site: An Update S Maramai, M Benchekroun, SE Ward, JR Atack Journal of medicinal chemistry 63 (7), 3425-3446, 2019 | 56 | 2019 |
| Disease‐Modifying Anti‐Alzheimer's Drugs: Inhibitors of Human Cholinesterases Interfering with β‐Amyloid Aggregation S Brogi, S Butini, S Maramai, R Colombo, L Verga, C Lanni, E De Lorenzi, ... CNS neuroscience & therapeutics 20 (7), 624-632, 2014 | 56 | 2014 |
| Multifunctional cholinesterase and amyloid beta fibrillization modulators. Synthesis and biological investigation S Butini, M Brindisi, S Brogi, S Maramai, E Guarino, A Panico, A Saxena, ... ACS medicinal chemistry letters 4 (12), 1178-1182, 2013 | 44 | 2013 |
| Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases S Butini, M Brindisi, S Gemma, P Minetti, W Cabri, G Gallo, S Vincenti, ... Journal of Medicinal Chemistry 55 (15), 6898-6915, 2012 | 43 | 2012 |
| Harnessing the role of HDAC6 in idiopathic pulmonary fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors G Campiani, C Cavella, JD Osko, M Brindisi, N Relitti, S Brogi, ... Journal of medicinal chemistry 64 (14), 9960-9988, 2021 | 35 | 2021 |
| Development of potent inhibitors of fatty acid amide hydrolase useful for the treatment of neuropathic pain M Brindisi, G Borrelli, S Brogi, A Grillo, S Maramai, M Paolino, M Benedusi, ... ChemMedChem 13 (19), 2090-2103, 2018 | 25 | 2018 |
| Development of novel cyclic peptides as pro-apoptotic agents M Brindisi, S Maramai, S Brogi, E Fanigliulo, S Butini, E Guarino, ... European Journal of Medicinal Chemistry 117, 301-320, 2016 | 25 | 2016 |
| Selective Kainate Receptor (GluK1) Ligands Structurally Based upon 1H-Cyclopentapyrimidin-2,4(1H,3H)-dione: Synthesis, Molecular Modeling, and … R Venskutonyte, S Butini, S Sanna Coccone, S Gemma, M Brindisi, ... Journal of medicinal chemistry 54 (13), 4793-4805, 2011 | 24 | 2011 |
| A stereoselective approach to peptidomimetic BACE1 inhibitors S Butini, E Gabellieri, M Brindisi, S Giovani, S Maramai, G Kshirsagar, ... European Journal of Medicinal Chemistry 70, 233-247, 2013 | 22 | 2013 |
| (S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and … S Brogi, M Brindisi, S Butini, GU Kshirsagar, S Maramai, G Chemi, ... Journal of Medicinal Chemistry 61 (5), 2124-2130, 2018 | 21 | 2018 |
| Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies M Brindisi, C Cavella, S Brogi, A Nebbioso, J Senger, S Maramai, A Ciotta, ... Future Medicinal Chemistry 8 (13), 1573-1587, 2016 | 21 | 2016 |
| Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties S Butini, S Gemma, M Brindisi, S Maramai, P Minetti, D Celona, ... Bioorganic & medicinal chemistry letters 23 (2), 492-495, 2013 | 21 | 2013 |
| Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition M Brindisi, S Brogi, S Maramai, A Grillo, G Borrelli, S Butini, E Novellino, ... RSC advances 6 (69), 64651-64664, 2016 | 20 | 2016 |
| Multitarget-directed ligands for neurodegenerative diseases: real opportunity or blurry mirage? M Benchekroun, S Maramai Future Medicinal Chemistry 11 (4), 261-263, 2019 | 18 | 2019 |
| Activation of the Wnt pathway by small peptides: rational design, synthesis and biological evaluation S Brogi, S Maramai, M Brindisi, G Chemi, V Porcari, C Corallo, L Gennari, ... ChemMedChem 12 (24), 2074-2085, 2017 | 14 | 2017 |
| Micellar catalysis for sustainable hydroformylation F Migliorini, F Dei, M Calamante, S Maramai, E Petricci ChemCatChem 13 (12), 2794-2806, 2021 | 13 | 2021 |
| Development of a practical and scalable route for the preparation of the deacetoxytubuvaline (dTuv) fragment of pretubulysin and analogs M Brindisi, S Maramai, A Grillo, S Brogi, S Butini, E Novellino, G Campiani, ... Tetrahedron Letters 57 (8), 920-923, 2016 | 7 | 2016 |
